Search company, investor...
Dascena company logo

Dascena

dascena.com

Founded Year

2014

Stage

Grant | Alive

Total Raised

$50M

About Dascena

Dascena develops machine learning algorithms to enable early disease intervention and improve care outcomes for patients. The company was founded in 2014 and is based in Houston, Texas.

Headquarters Location

12333 Sowden Rd., Ste B

Houston, Texas, 77080,

United States

(510) 826-9508

Missing: Dascena's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

ESPs containing Dascena

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

EXECUTION STRENGTHMARKET STRENGTHLEADERHIGHFLIEROUTPERFORMERCHALLENGER
Healthcare / Healthcare Providers Tech

Companies in this space compile datasets and analysis for populations to identify trends and risk groups.

Dascena named as Challenger among 15 other companies, including Aledade, ArborMetrix, and ClosedLoop.ai.

Missing: Dascena's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing Dascena

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Dascena in 1 CB Insights research brief, most recently on May 7, 2020.

Expert Collections containing Dascena

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dascena is included in 7 Expert Collections, including Digital Health.

D

Digital Health

21,956 items

Startups recreating how healthcare is delivered

A

Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

V

Value-Based Care & Population Health

1,253 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

M

Medical Devices

8,763 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

H

Health Monitoring & Diagnostics

2,541 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

Dascena Patents

Dascena has filed 1 patent.

The 3 most popular patent topics include:

  • Attachment theory
  • Caregiving
  • Clinical research
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/15/2015

Diabetes, Dimension reduction, Machine learning, Medical equipment manufacturers, Intensive care medicine

Application

Application Date

6/15/2015

Grant Date

Title

Related Topics

Diabetes, Dimension reduction, Machine learning, Medical equipment manufacturers, Intensive care medicine

Status

Application

Latest Dascena News

Longitude Capital Expands Biotechnology Practice With Matthew Young, Former Grail COO and Jazz EVP, and Cadre of New Talent

Nov 17, 2022

Menlo Park, California, UNITED STATES MENLO PARK, Calif., BOSTON, and GREENWICH, Conn., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Longitude Capital, a leading healthcare venture capital firm focused on venture growth investments in biotechnology, medical technology, and health solutions, announced that veteran life sciences executive Matthew Young has joined the firm as Managing Director. Mr. Young joins Longitude Capital after almost a decade in leadership positions at GRAIL and Jazz Pharmaceuticals, and 20 years in investment banking. "Matt's corporate development, financial, and C-suite operating experience spans life science businesses across multiple sectors and stages, all of which will contribute to our investment decision-making and to supporting our portfolio companies with strategic counsel," said Longitude Managing Director and Co-founder Patrick Enright. "We are extremely excited to have Matt join our team as we continue to invest in innovative biotechnology companies that, like us, seek to transform the healthcare industry." Prior to joining Longitude Capital, Mr. Young was the Chief Operating Officer and Chief Financial Officer of GRAIL, a developer of blood cancer tests that was acquired by Illumina (ILMN) for $8 billion in 2021. From 2013 to 2019, Mr. Young held positions of increasing responsibility at Jazz Pharmaceuticals (JAZZ), a Longitude portfolio company, most recently as Executive Vice President and Chief Financial Officer. Prior to JAZZ, Mr. Young was an investment banker for nearly 20 years at Barclays Capital, Citigroup, Lehman Brothers, and Merrill Lynch, where he advised and led financings for hundreds of emerging and established life science companies. Additionally, Mr. Young served on the board of PRA Health Sciences (PRAH) until its acquisition by ICON plc for $12 billion in 2021, and currently serves as Lead Independent Director and Chairman of the audit committee of CytomX Therapeutics (CTMX) as well as a board member of Alpha-9 Therapeutics. "I have focused my career on supporting companies across the healthcare continuum that strive to improve patients’ lives by building sustainable businesses that meaningfully improve the standard of care and outcomes. I’m excited to help shape Longitude’s biotechnology practice in its pursuit and advancement of critical therapeutic and diagnostic solutions that will further our shared mission," said Mr. Young. Longitude Capital also announced a cadre of new additions to its biotechnology practice in 2022 in support of the Firm’s continued growth in this core sector: Brahma Kumar, MD, PhD – Dr. Kumar is a Vice President on the Biotechnology team and is based in the Greenwich and Boston offices. Prior to joining the Firm, Dr. Kumar was an Engagement Manager at McKinsey & Co., where he focused on R&D strategy for biopharmaceutical clients. Dr. Kumar holds a PhD in Immunology, an MD from Columbia University, and a BA in Economics from Johns Hopkins University. Cindy Wang, PhD – Dr. Wang is a Vice President on the Biotechnology team and is based in the Menlo Park office. Prior to joining the Firm, Dr. Wang most recently served as a Senior Director of Strategy & Corporate Development at Dascena, a Longitude portfolio company. Prior to Dascena, Dr. Wang was an Engagement Manager at L.E.K. Consulting, where she consulted for life sciences companies on drug development, and commercial and portfolio strategy. Dr. Wang holds a PhD in Molecular and Cell Biology from the University of California, Berkeley, and a BA in Chemical and Physical Biology from Harvard University. Zack Ely, PhD – Dr. Ely is a Senior Associate on the Biotechnology team and is based in the Boston office. Prior to joining the Firm full-time, Dr. Ely was a Research Fellow under the Longitude Research Network (LRN), the Firm’s dedicated arm for identifying cutting-edge innovations within sectors, therapeutic areas, or technologies of interest. Dr. Ely holds a PhD in Biology from the Massachusetts Institute of Technology, where he specialized in genome engineering and cancer immunology. Dr. Ely also holds a BA in Molecular and Cellular Biology from Vanderbilt University. About Longitude Capital Longitude Capital is a leading healthcare venture capital firm that invests in transformative biotechnology, medical technology, and health solutions companies seeking to improve clinical outcomes, enhance quality of life, and drive efficiency of healthcare delivery. Founded in 2006, Longitude Capital invests in both privately held and publicly traded companies through a variety of investment approaches. Longitude Capital has offices in Menlo Park, CA, Greenwich, CT, and Boston, MA. For more information, please visit  www.longitudecapital.com or LinkedIn . Source: Longitude Capital

Dascena Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Dascena Rank

Dascena Frequently Asked Questions (FAQ)

  • When was Dascena founded?

    Dascena was founded in 2014.

  • Where is Dascena's headquarters?

    Dascena's headquarters is located at 12333 Sowden Rd., Ste B, Houston.

  • What is Dascena's latest funding round?

    Dascena's latest funding round is Grant.

  • How much did Dascena raise?

    Dascena raised a total of $50M.

  • Who are the investors of Dascena?

    Investors of Dascena include National Institutes of Health, Longitude Capital, Frazier Healthcare Partners and Euclidean Capital.

  • Who are Dascena's competitors?

    Competitors of Dascena include AlgoDx, Clearsense, Upfront Healthcare, ClosedLoop.ai, Syapse, Abacus Insights, Lumiata, Clarify Health, Heaps Health Solutions, Health Fidelity and 17 more.

Compare Dascena to Competitors

Aetion Logo
Aetion

Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.

Ambient Clinical Analytics Logo
Ambient Clinical Analytics

Ambient Clinical Analytics makes software tools that support hospital emergency rooms and intensive care units. It sells healthcare data assimilation, communication, and analytics-based decision support tools that support the ICU, Operating Room and Emergency Department. Its business model is supported by software license fees, SaaS, Cloud and system integration revenue.

H
Heaps Health Solutions

Heaps Health Solutions is a global health tech platform and SaaS provider that leverages advanced data analytics, artificial intelligence, and machine learning to revolutionize healthcare delivery and payment models.

Syapse Logo
Syapse

Syapse develops applications that enable the use of omics profiles in diagnosing and treating patients at diagnostic companies, research institutions, medical centers, and payers. The Syapse Discovery application provides an end-to-end solution for companies and laboratories deploying sequencing-based diagnostics, from patient sample received to physician report delivered. Discovery's configurable semantic data structure enables users to bring omics data together with traditional medical information to develop and deliver diagnostic tests. The platform's open interfaces enable bioinformaticians and biologists to use their favorite computational tools and annotations. The company was formerly known as BDLicense. Syapse was founded in 2008 and is based in San Francisco, California.

Cedar Gate Technologies Logo
Cedar Gate Technologies

Cedar Gate Technologies is a value-based care performance management analytic and operating company. Cedar Gate provides high-performance analytic and operating systems that enable users to meet and exceed the performance thresholds of risk-based contracts and programs.

Clarify Health Logo
Clarify Health

Clarify Health collects records of rendered healthcare in the United States for the purpose of providing more granular and precise analytics to healthcare organizations, spanning from providers to payers and life sciences. Clarify's software solutions are fueled by a patient-level data set and incorporate clinical, claim, prescription, lab and socio-behavioral determinants of health data. Its analytics platform is powered by a technology stack inspired by those used in banking and logistics and provides doctors and insurers greater visibility into cost, quality, referrals, utilization, and member risk. The company is also helping life sciences organizations analyze and integrate rich data to determine the optimal sites and designs for clinical trials as well as accelerate clinical development timelines. The company was founded in 2015 and is based in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.